Tech Center 1600 • Art Units: 1613 1615
This examiner grants 28% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18408546 | THERAPEUTIC AGENTS AND THEIR USE FOR TREATING CHRONIC WOUNDS | Non-Final OA | President and Fellows of Harvard College |
| 17906433 | IMPLANTABLE CELL CHAMBER DEVICE AND USES THEREOF | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 17904553 | CROSSLINKED POLY(LACTIDE-CO-GLYCOLIDE) (PLGA)-DIMETHACRYLATE COATINGS AND METHODS OF USE | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17914134 | METHODS FOR TISSUE REGENERATION AND KITS THEREFOR | Non-Final OA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
| 17762130 | KIT, SYSTEM AND METHOD FOR PREPARING AND USE OF A PERIOXIDE-CONTAINING COMPOSITION | Final Rejection | KONINKLIJKE PHILIPS N.V. |
| 17789262 | OCTENIDINE SALT ANTIMICROBIAL MEDICAL ARTICLES | Non-Final OA | Solventum Intellectual Properties Company |
| 17599440 | DYEING PROCESS USING PEROXYGENATED SALTS AND A SUBSTRATE COMPRISING OXIDATION DYES | Final Rejection | L'OREAL |
| 18367131 | IONIC COMPOUNDS FOR MEDICAL DEVICE APPLICATIONS | Non-Final OA | Becton, Dickinson and Company |
| 17796925 | METHODS FOR MICROWAVE SYNTHESIS OF DEGRADABLE POLYMERS FOR DRUG DELIVERY | Final Rejection | The General Hospital Corporation |
| 19027175 | ENTERIC COATED TABLET | Final Rejection | ZERIA PHARMACEUTICAL CO., Ltd. |
| 18017583 | COMPOSITION FOR PREVENTING ADHESION | Final Rejection | The University of Tokyo |
| 18177659 | SILK FIBROIN COMPOSITE MATERIAL WITH INCREASED CONTENT OF BETA-SHEET AND METHOD FOR PREPARING THE SAME | Final Rejection | Industry-Academic Cooperation Foundation, Yonsei University |
| 18246449 | DRUG COATING, DRUG-COATED BALLOON AND PREPARATION METHOD THEREOF | Non-Final OA | LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD. |
| 18999039 | Surfactant Formulations for Inhalation | Final Rejection | Merz Pharmaceuticals, LLC |
| 18018275 | ANTIMICROBIAL SILK NANOPARTICLES AND METHODS FOR MAKING AND USING THE SAME | Final Rejection | University of Georgia Research Foundation, Inc. |
| 18016095 | ANTI-MICROBIAL MEDICAL GRADE POLYMER SUBSTRATES WITH ANTI-FUNGAL AND ANTI-BACTERIAL PROPERTIES | Final Rejection | University of Georgia Research Foundation, Inc. |
| 18010653 | DRUG-LOADED MEDICAL DEVICE AND PREPARATION METHOD, DRUG BALLOON, AND DRUG COATING PREPARATION METHOD | Final Rejection | SHANGHAI MICROPORT MEDICAL (GROUP) CO., LTD. |
| 17560819 | METHOD FOR MANUFACTURING ORALLY DISINTEGRATING TABLET, AND ORALLY DISINTEGRATING TABLET | Non-Final OA | SAWAI PHARMACEUTICAL Co., Ltd. |
| 17629520 | Personal Care Compositions and Methods | Final Rejection | Colgate-Palmolive Company |
| 18696555 | DENTAL COMPOSITION | Non-Final OA | GC Corporation |
| 18018027 | MICROSPHERE DRUG COATED MEDICAL DEVICES, MATERIALS AND METHODS | Final Rejection | BIOTRONIK AG |
| 17916215 | NANOFIBER-ENABLED ENCAPSULATION DEVICES AND USES THEREOF | Non-Final OA | CORNELL UNIVERSITY |
| 17628695 | NRF2 ACTIVATION FOR TREATMENT OF NEPHROGENIC DIABETES INSIPIDUS | Non-Final OA | University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
| 18744338 | METHOD FOR AMPLIFYING EXPRESSION OF TRANSPORTER-RELATED GENE IN EPIDERMAL CELLS | Non-Final OA | J-Network, Inc. |
| 18250754 | GASTRORETENTIVE PHARMACEUTICAL DOSAGE FORM | Non-Final OA | TRIASTEK, INC. |
| 18049237 | Biological Material And Preparation Method Therefor | Final Rejection | VENUS MEDTECH (HANGZHOU) INC. |
| 18034561 | BIOCOMPATIBLE MATERIAL AND METHOD OF PRODUCING SAME | Final Rejection | Maruemu Works Co., LTD. |
| 18425309 | HEAT PATCH CAPABLE OF TARGETED DRUG DELIVERY BASED ON MONROE EFFECT | Non-Final OA | Longxi Cheezheng Medicinal Materials Co., Ltd. |
| 18563595 | FLUID COSMETIC COMPOSITIONS WITH UNUSUAL RHEOLOGIC CHARACTERISTICS, POLYMERS ADAPTED TO PROVIDE THE ABOVE SAID CHARACTERISTICS AND THEIR SYNTHESIS | Non-Final OA | INTERCOS S.p.A. |
| 18560449 | A WATER-SOLUBLE GLASS RUMEN BOLUS | Non-Final OA | BIMEDA ANIMAL HEALTH LIMITED |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy